• News
  • SAN DIEGO
  • BioTech

Arena enters license agreement with Ildong Pharmaceuticals

San Diego-based Arena Pharmaceuticals Inc. (Nasdaq: ARNA) Wednesday announced it has entered into a co-development and license agreement with Ildong Pharmaceutical Co. Ltd. for temanogrel, Arena's internally discovered inverse agonist of the serotonin 2A receptor.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Arena Pharmaceuticals Inc.

Company Website

6166 Nancy Ridge Drive
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ARNA
4.17
  0.16  
+ 3.99%
2,852,213,000
7.97
3.26

Insider Trade Data

Date Insider Shares Type Value
09/17/2014 Lief, Jack 100,000 Exchange $149,000
07/01/2014 Lief, Jack 223,525 Sell $1,308,582
06/27/2014 Belcher, Donald D 2,473 Exchange $13,503
06/27/2014 Belcher, Donald D 2,473 Sell $14,467
06/27/2014 Belcher, Donald D 2,473 Exchange $13,503

Arena Pharmaceuticals Inc. Executive(s):

Jack Lief

  • Chief Executive Officer, President, Chairman

Similar Companies

NAICS - 424210 - Drugs and Druggists' Sundries Merchant Wholesalers
SIC - 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS' SUNDRIES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
Subscribe Today!